[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Therapy Trends Consensus Outlook: Hepatitis C

November 2012 | | ID: TEA1E942F50EN

US$ 4,995.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
The worldwide hepatitis C (HCV) market is forecast to grow from $3.8 billion in 2011 to $14.5 billion in 2020. The catalysts for this growth include a boost in diagnosis rates following an increase in screening, and the introduction more effective and tolerable pipeline agents.

Therapy Trends Consensus Outlook: Hepatitis C analyses the global HCV market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:
  • An in-depth 9-year consensus forecast report based on multiple analyst forecasts, mapping the predicted impact of future events to product performance
  • A detailed and interactive forecast data analysis spreadsheet model comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2006 to 2020
  • Forecast and analysis updates driven by events and developments in the market (available, at no charge, for the 12 month period following your order).
Understand the Unique Benefits of Consensus Outlook: Hepatitis C

Produce robust plans based on independent, unbiased, reliable drug sales forecasts.

Numbers you can trust - base your market view on critical insights uncovered from sources with unrivalled market knowledge and intimacy.

Always up-to date product sales forecasts. Introduce another level of confidence into your projections.

Visualise and correlate the impact future events will have on driving the commercial success of your products versus those of the competition.

Focus on the products, companies and catalysts that will define the future market landscape.

Chart the trends that are likely to play out over the next five years.

Mark your calendar with the listing of key events to watch.

Mapping Future Events to Product Sales Forecasts

The forecast analysis report component of Consensus Outlook: Hepatitis C delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2006-11) is based on company information, and the nine-year (2012-20) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.

Report features:
  • Historical HCV sales from 2006-2011
  • Forecast HCV sales from 2012-2020
  • Key competitors and drug developers
  • Predicted product positioning
  • Current and late-stage pipeline drugs
  • Future event mapping to forecast data points
  • Comparative clinical trial results
Interactive Product and Market Forecast Data Model

FirstWord's HCV forecast model presents product sales and market size data for the period 2006-2020 in a rich set of tables and charts covering the following key parameters:
  • Market size
  • Product sales
  • Company forecasts
  • Company, brand, and drug class
  • Mechanism of action
  • Future events
Forecasts and Analysis Updated Within Days of Major Market Events

Stay a step ahead with Therapy Trends Consensus Outlook updates. Over the next 12 months, you will receive updated market analysis and forecast reports each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event's occurrence.

Whether it's a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.

An approach backed by unrivalled knowledge and market intimacy

For each Therapy Trends report, FirstWord analysts produce a data analysis module, a Consensus Outlook, which provides annual historical and forecast, product-level sales data. Historical sales data is derived from company information, while the five-year (2012-16) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

Once a Therapy Trends data module is published, FirstWord analysts subsequently collate and evaluate the latest relevant reports published by equity research analysts and feed relevant updated forecasts into the Therapy Trends forecast model.

Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections – produced either internally or by other third parties – can be assessed.

Equity research teams utilize a selection of analytical frameworks to generate product level forecasts, focusing heavily on patient and event based modelling. In addition to consensus forecasting, FirstWord Therapy Trend data modules also collate and analyse the key future events that are anticipated to impact product level forecasts and shape the broader context of a specific disease area – to produce a '€˜consensus calendar'€ of events designed to help inform FirstWord clients on how the market will evolve.

Leading equity research analysts have a deep intimacy with the prescription pharmaceutical market and the companies they cover; supported by unrivalled research resources, this highly analytical insight extends to the product franchises of these companies (driven by a 'bottom-up' forecasting methodology) and the strategic protocols being pursued by company management.

Hepatitis C Marketplace
Key Hepatitis C Developers
Hepatitis C Class Dynamics


Incivek (telaprevir; Vertex Tibotec/Mitsubishi Tanabe) forecast
Victrelis (boceprevir; Merck) forecast
PegaSys (pegylated interferon-alpha; Roche) forecast
PegIntron (pegylated interferon-alpha; Merck) forecast
Sofosbuvir (GS-7977, Gilead) forecast
Abbott franchise (ABT-333/ABT-450/ABT-267; Abbott) forecast
Bristol-Myers Squibb franchise (daclastasvir/asunaprevir) forecast
Sovaprevir (ACH-1625; Achillion Pharmaceuticals) forecast
MK-5172 (Merck) forecast
Vaniprevir (MK-7009; Merck) forecast
Simeprevir (TMC435; Medivir/Tibotec) forecast
VX-222 (Vertex) forecast

More Publications